FEB 0 8 2005 E

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Porunellor A. Mathew

and Kent Boles

Serial No.:

10/021,741

EXPEDITED PROCEDURE EXAMINING GROUP 1642

RESPONSE UNDER 37 C.F.R. 1.116

Filed:

12/12/2001

For:

IMMUNO-ACTIVATION OF CS1 RECEPTOR IN NATURAL

KILLER CELLS TO INHIBIT TUMOR CELL GROWTH.

Group No.:

1642

Examiner:

Canella, Karen A.

Mail Stop AF Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Mail Stop AF, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on February 2, 2004.

M. Alford

(Printed or typed name of person signing the certificate)

(Signature of the person signing the certificate)

AMENDMENT AFTER FINAL UNDER 37 C.F.R. § 1.116

Responsive to the Final Office Action dated December 2, 2004, having a shortened statutory period for responding expiring March 2, 2005, and the two-month period expiring on February 2, 2005, please amend the above-identified patent application as follows:

In the Claims:

PLEASE AMEND CLAIMS AS FOLLOWS:

- 1. (Withdrawn) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a proteinaceous molecule or biological equivalent, wherein the encoded proteinaceous molecule or biological equivalent has a predicted peptide sequence homologous to a subset of a CD2 family of receptors, a predicted length of about 335 amino acids; a predicted intracellular domain of about 85 amino acid residues; a predicted extracellular domain of about 225 amino acid residues; and a predicted single transmembrane domain of about 25 amino acid residues.
- 2. (Withdrawn) The isolated nucleic acid molecule of claim 1, wherein the nucleic acid sequence comprises nucleotides of SEQ ID NO 1.

1